Fig. 7

Slc11a1 Knockdown in Mouse Models Leads to Reduced ROS, Ferrous Ions and NETs in Neutrophils. A Schematic representation of generating Slc11a1 knockdown mice using AAV constructs and constructing a TCb chemotherapy mouse model, B q-PCR analysis of Slc11a1 mRNA expression in neutrophils from mouse models. Significant increases in Slc11a1 mRNA expression in neutrophils from TCb-treated mice were reversed in Slc11a1-knockdown TCb-treated mice, C–E detection of ferrous ion levels in neutrophils from mouse models. Elevated ferrous ion content in neutrophils from TCb-treated mice was notably reversed in Slc11a1-knockdown mice, F, G measurement of ROS levels in neutrophils from mouse models. Elevated ROS levels in neutrophils from TCb-treated mice were significantly mitigated in Slc11a1-knockdown mice, H quantification of dsDNA in plasma from mouse models. Increased plasma dsDNA concentrations in TCb-treated mice were significantly attenuated in Slc11a1-knockdown mice, I analysis of MPO and histone H3 levels in plasma from mouse models. Elevated concentrations of MPO and histone H3 in plasma from TCb-treated mice were significantly reversed in Slc11a1-knockdown mice, J assessment of vWF and Syndecan-4 levels in plasma from mouse models. Increased plasma concentrations of vWF and Syndecn-4 in TCb-treated mice were significantly diminished in Slc11a1-knockdown mice. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001